* HYBRIGENICS *
1997 - IDF
Paris
www.hybrigenics.com Discovery, Drugs
(also, Services, Research)
Key words: Protein-protein interaction, Cancer, Inecalcitol, D-vitamin, Protease inhibitor, Protein-interactions maps (PIMs)
Mission: to develop internal R&D programs on innovative target and therapeutics against cancer and to market proprietary high throughput technology and bioinformatics platforms focused on identification, validation and inhibition of protein interactions
Clients: Prescribers
contact@hybrigenics.com
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS | | Academic |
Managing Dir.: Delansorne (Rémi) [born 1959, Vet.D., Ph.D., ex-Theramex (Merck KgAa)]
Sc.Dir.: Daviet (Laurent) [Ph.D. molecular biology]
Oper.Dir.: Petitville (Didier) [ex-Institut Pasteur]
Fin.Dir.: Cohen, Eric [Ms. finance (Dauphine), MBA (LBS), ex-Teva, Mazars, CityJeux, Radio BFM]
BusDev:
Financers: Medicis, Rendex, Sofindev, IMH, Lombard Odier, Alafi Capital, Life Science Partners, Banexi V.P., C.F. Edmond de Rothschild, Public | Turnover (M€) : 2.8 (2006)
Total funding (M€) : n.a.
Last funding (M€) : 6.2
Focus : Cancers
Position : Preclin
Company confirm : neutral |
History | DATE | MILESTONE | TYPE | TIME | | 2008 .09 | Financing (no interest loan) : 1.4 M€, by OSEO, to support its ongoing clinical development program of inecalcitol in prostate cancer | DEBT | [11 years] |
| 2007 .12 | Listing on Alternext : 6.2 M€ | PBO | [10 years] |
| 2005 .09 | Nomination : Rémi Delansorne, as CEO (previously CSO since 2004), replacing Donny Strosberg | ORGN | [8 years] |
| 2003 .05 | Acquisition of Semaia (Holland), a biotech focused on oncology | ACQ+ | [6 years] |
| 2002 .04 | 3rd round-financing : 16.8 M€, led by Life Science Partners, with Banexi V.P., C.F. Edmond de Rothschild, and previous shareholders | RFINC | [5 years] |
| 2000 .10 | 2nd round-financing : 19.5 M€, led by Alafi Capital, Lombard Odier, Medicis, Rendex, Sofindev, and previous shareholders | RFINB | [3 years] |
| 1999 .06 | 1st round-financing : 9.1 M€, led by Auriga Partners, IMH, HealthCap, and previous shareholders | RFINA | [2 years] |
| 1998 .05 | Seed financing : 1 M€, by Apax Partners, Altamir | SFIN | [1 year] |
| 1998 .04 | Licensing-in of any discovery by Institut Pasteur on protein-protein interaction, with right of first refusal and exclusivity | LICIN | [1 year] |
| 1997 .12 | Company founded by Prof. Arthur Donny Strosberg (CEO), Pierre Legrain, Jacques Camonis, and Richard Benarous | ORGF | [0 year] | Actualisation / Updating: 31-Oct-2008 |
|
